Sapna Srivastava, Ph.D., Chief Financial Officer

Dr. Srivastava is the Chief Financial Officer at eGenesis and is a seasoned industry executive with extensive experience leading finance activities and guiding corporate strategy.  Most recently, Dr. Srivastava served as the chief financial and strategy officer at Abide Therapeutics (acquired by Lundbeck), prior to which she held a similar role at Intellia Therapeutics. In these roles, she has played a key role in equity financings including a successful initial public offering, strategic alliances including M&A, as well as in shaping the strategic direction of the company.  She also has experience as a board member for public and private biotechnology companies. Before Intellia, Dr. Srivastava spent more than a decade on Wall Street as a senior biotechnology analyst for Goldman Sachs, Morgan Stanley and ThinkEquity Partners, LLC. She began her career as a research associate at J.P. Morgan.

Dr. Srivastava earned her B.S. in Biology from St. Xavier’s College at the University of Mumbai and her Ph.D. in neuroscience from the New York University School of Medicine.